Dechra Pharmaceuticals plc (DPH) Receives Average Recommendation of “Buy” from Analysts
Shares of Dechra Pharmaceuticals plc (LON:DPH) have earned a consensus rating of “Buy” from the eight analysts that are covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is GBX 1,733.50 ($22.42).
Several equities research analysts recently weighed in on the stock. N+1 Singer reiterated a “buy” rating and set a GBX 1,666 ($21.55) price objective on shares of Dechra Pharmaceuticals plc in a research note on Thursday, July 6th. Numis Securities Ltd reiterated an “add” rating and set a GBX 1,890 ($24.44) price objective on shares of Dechra Pharmaceuticals plc in a research note on Thursday, July 6th. Investec reiterated a “buy” rating and set a GBX 1,840 ($23.80) price objective on shares of Dechra Pharmaceuticals plc in a research note on Thursday, July 6th. Finally, Stifel Nicolaus reiterated a “hold” rating and set a GBX 1,550 ($20.05) price objective on shares of Dechra Pharmaceuticals plc in a research note on Tuesday, July 11th.
In other Dechra Pharmaceuticals plc news, insider Ian Page sold 134,500 shares of the firm’s stock in a transaction that occurred on Wednesday, June 21st. The shares were sold at an average price of GBX 1,927 ($24.92), for a total value of £2,591,815 ($3,352,062.86).
TRADEMARK VIOLATION NOTICE: “Dechra Pharmaceuticals plc (DPH) Receives Average Recommendation of “Buy” from Analysts” was originally published by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/dechra-pharmaceuticals-plc-dph-receives-average-recommendation-of-buy-from-analysts/1530084.html.
Shares of Dechra Pharmaceuticals plc (DPH) traded down 0.37% during mid-day trading on Tuesday, hitting GBX 1894.00. The stock had a trading volume of 75,999 shares. Dechra Pharmaceuticals plc has a 52-week low of GBX 1,225.00 and a 52-week high of GBX 1,970.00. The firm’s market cap is GBX 1.76 billion. The firm has a 50 day moving average price of GBX 1,770.38 and a 200 day moving average price of GBX 1,730.41.
Dechra Pharmaceuticals plc Company Profile
Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development.
Receive News & Ratings for Dechra Pharmaceuticals plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals plc and related companies with Analyst Ratings Network's FREE daily email newsletter.